Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRISPR screens identify a novel combination treatment targeting BCL-XL and WNT signaling for KRAS/BRAF-mutated colorectal cancers.

Oncogene - 1 May 2021

Jung Hae Rim, Oh Yumi, Na Deukchae, Min Seoyeon, Kang Jinjoo, Jang Dongjun, Shin Seungjae, Kim Jiwon, Lee Sang Eun, Jeong Eui Man, An Joon Yong, Sung Chang Ohk, Lee Won-Suk, Lee Charles, Cho Sung-Yup

Abstract excerpt

Metastatic or recurrent colorectal cancer (CRC) patients require systemic chemotherapy, but the therapeutic options of targeted agents remain limited. CRC patients with KRAS or BRAF gene mutations exhibit a worse prognosis and are resistant to anti-EGFR treatment. Previous studies have shown that the expression of anti-apoptotic protein BCL-XL is increased in CRC patients with KRAS/BRAF mutations, suggesting...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aniline Compounds
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to bcl-X Protein

Share to CRISPR-Cas Systems

Share to Proto-Oncogene Proteins p21(ras)

Share to Sulfonamides

Share to Wnt Signaling Pathway

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 33846570
DOI: 10.1038/s41388-021-01777-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRISPR screens identify a novel combination treatment targeting BCL-XL and WNT signaling for KRAS/BRAF-mutated colorectal cancers.PMID 33846570Read ↗

Bcl-xL is a key mediator of apoptosis following KRAS <sup>G12C</sup> inhibition in <i>KRAS</i> <sup> <i>G12C</i> </sup> mutant colorectal cancerSemantic proximity Read ↗

A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers.Semantic proximity Read ↗

Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancerSemantic proximity Read ↗

mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.Semantic proximity Read ↗

Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.Semantic proximity Read ↗

Bcl-xL is an oncogenic driver in colorectal cancer.Semantic proximity Read ↗

BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancerSemantic proximity Read ↗

Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian CancerSemantic proximity Read ↗

Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer.Semantic proximity Read ↗

CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicitySemantic proximity Read ↗

Genome-wide CRISPR Screening Identifies NFκB and c-MET as Druggable Targets to Sensitize Lenvatinib Treatment in Hepatocellular CarcinomaSemantic proximity Read ↗

Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.